Biogen Idec Inc (BIIB) 318.78 $BIIB Acorda 2Q E
Post# of 273323
Posted On: 08/01/2015 2:48:50 AM
Biogen Idec Inc (BIIB) 318.78 $BIIB
Acorda 2Q Earnings & Revenues Top, Ampyra in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Jul 31, 2:43PM CDT
Acorda (ACOR) narrowed its 2015 guidance for Ampyra to $410 million - $420 million from $405 million - $420 million.
BIIB: 318.78 (+1.78), LGND: 108.26 (+0.48), AMAG: 63.90 (-0.87), ACOR: 34.36 (+0.13)
Price Isn't a Problem for Gilead Sciences
at The Street - Thu Jul 30, 10:00AM CDT
Drugmaker has one of the best showings of earnings season.
BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04), PFE: 36.06 (+0.33), MRK: 58.96 (+0.44), ABBV: 70.01 (-0.15), CELG: 131.25 (-0.63)
Attention New Biotech Investors: Biogen Inc's Recent Weakness Is Your Opportunity
Brian Feroldi, The Motley Fool - Motley Fool - Thu Jul 30, 8:38AM CDT
Investing in biotech stocks can be very intimidating for beginners, as many investors consider the word "biotech" to be synonymous with "risk". Press releases are filled with scientific jargon, many companies are losing money, and normal valuation...
BIIB: 318.78 (+1.78)
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Jul 30, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA
BIIB: 318.78 (+1.78), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), REGN: 553.66 (+6.56), XOMA: 0.73 (-0.08)
Troubled Stocks Go From Worst to First
at The Street - Wed Jul 29, 3:05PM CDT
Oil- and commodity-related shares perform well.
BIIB: 318.78 (+1.78), ESPR: 62.00 (-2.25), VDSI: 20.39 (-0.78), FB: 94.01 (-1.20), BEAT: 12.23 (+0.54), DATA: 104.74 (-2.10)
Sorry, No Fed Effect Today
at The Street - Wed Jul 29, 1:22PM CDT
The market did its usual jig on the news and went along its merry way.
BIIB: 318.78 (+1.78), ESPR: 62.00 (-2.25), VDSI: 20.39 (-0.78), FB: 94.01 (-1.20), BEAT: 12.23 (+0.54), DATA: 104.74 (-2.10)
Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 29, 10:48AM CDT
Last week saw several major biotech companies like Biogen (BIIB) and AbbVie (ABBV) reporting second quarter results.
BIIB: 318.78 (+1.78), VRTX: 135.00 (-0.46), ALXN: 197.44 (-1.85), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), REGN: 553.66 (+6.56), XOMA: 0.73 (-0.08)
Make Sure You Don't Get Caught in a Breakdown
at The Street - Wed Jul 29, 9:11AM CDT
Nothing much sticks out to the upside right now.
BIIB: 318.78 (+1.78), ESPR: 62.00 (-2.25), VDSI: 20.39 (-0.78), FB: 94.01 (-1.20), BEAT: 12.23 (+0.54), DATA: 104.74 (-2.10)
Stock Market News for July 29, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 9:10AM CDT
Benchmarks gained over 1% on Tuesday as investors focused on upbeat earnings results, ignoring the selloff in China’s stock market
BIIB: 318.78 (+1.78), F: 14.83 (-0.27), RIG: 13.26 (-0.69), GILD: 117.86 (-0.04), PFE: 36.06 (+0.33), COP: 50.34 (-1.73), XOM: 79.21 (-3.80), AMGN: 176.59 (+4.90), DD: 55.76 (+0.17), CVX: 88.48 (-4.55), SLB: 82.82 (-0.70), UPS: 102.36 (+0.96), CELG: 131.25 (-0.63)
5 Stocks Insiders Love Right Now
at The Street - Wed Jul 29, 7:14AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
RDUS: 78.32 (+3.08), ZINC: 8.28 (+0.21), BIIB: 318.78 (+1.78), MJN: 88.39 (-1.09), DPZ: 113.84 (unch)
Biogen Stock Remains Deeply Oversold
at The Street - Wed Jul 29, 5:00AM CDT
Three ways to profit after last Friday's crazy freefall.
BIIB: 318.78 (+1.78)
Gilead Q2 Earnings: KAPOW! BAM! BOOM! (Yes, That Good)
at The Street - Tue Jul 28, 3:15PM CDT
Gilead Sciences will not be blamed for a cooling of the biotech bull market, if any such thing exists.
BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04)
Amgen Stock Clears Buy Point Ahead Of Earnings
at Investor's Business Daily - Tue Jul 28, 1:33PM CDT
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first...
AGN: 331.15 (+2.28), BIIB: 318.78 (+1.78), SHPG: 266.81 (+4.29), MYL: 55.99 (-0.36), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), TEVA: 69.02 (-0.05)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Biogen, Inc.
PR Newswire - Tue Jul 28, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Biogen, Inc. ("Biogen" or the "Company"
(NasdaqGS: BIIB -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
BIIB: 318.78 (+1.78)
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 165.83 (+6.66), BIIB: 318.78 (+1.78), LGND: 108.26 (+0.48), REGN: 553.66 (+6.56), EXEL: 5.73 (+0.19)
Watching Twitter for Moves at Teva and Biogen
at The Street - Tue Jul 28, 7:28AM CDT
Twitter sentiment predicts the big moves in two healthcare stocks-NYMX and BIIB.
BIIB: 318.78 (+1.78), TEVA: 69.02 (-0.05)
3 Big Biotech Buybacks That Investors Should Love
Brian Feroldi, The Motley Fool - Motley Fool - Tue Jul 28, 6:03AM CDT
Source: Images Of Money/Flickr Creative Commons. Large-cap biotech stocks have been on a tear over the past few years, crushing the overall market return. Thanks to strong execution and a slew of new drug launches, these companies have found...
BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04), CELG: 131.25 (-0.63)
Biogen & the Parkinson's Institute and Clinical Center reports strategic alliance to form novel tools and programmes to accelerate research and the development of new treatments in Parkinson's disease
M2 - Tue Jul 28, 5:33AM CDT
Biotechnology company Biogen (NasdaqGS:BIIB) revealed on Monday the establishment of a strategic alliance with the Parkinson's Institute and Clinical Center, to enhance the understanding of the underlying biology of Parkinson's disease (PD) and the creation of novel tools and programmes that could accelerate research and the development of new PD treatments.
BIIB: 318.78 (+1.78)
'Mad Money' Lightning Round: Sell, Sell, Sell SanDisk
at The Street - Tue Jul 28, 5:00AM CDT
Cramer thinks Cerus is a nice speculative stock, says to wait on ConocoPhillips and to buy 3M at $142.
CERS: 5.43 (+0.09), MMM: 151.34 (-0.23), BIIB: 318.78 (+1.78), ISIS: 54.93 (+1.76), MDSO: 53.80 (-0.22), COP: 50.34 (-1.73), SNDK: 60.29 (-0.26)
Jim Cramer's 'Mad Money' Recap: Beware the Market's FANGs
at The Street - Mon Jul 27, 7:16PM CDT
Cramer says this is the thinnest market we've seen in ages, and that's not good.
CERS: 5.43 (+0.09), MMM: 151.34 (-0.23), AMZN: 536.15 (-0.61), BIIB: 318.78 (+1.78), MDLZ: 45.13 (-0.14), EA: 71.55 (-0.75), SNA: 164.80 (+0.42), NKE: 115.22 (+0.21), MDSO: 53.80 (-0.22), FB: 94.01 (-1.20), FCX: 11.75 (-0.09), COP: 50.34 (-1.73), DIS: 120.00 (-0.03), NFLX: 114.31 (+2.75), ISIS: 54.93 (+1.76), QLIK: 40.46 (-0.04), KHC: 79.47 (+0.26), GOOGL: 657.50 (-7.06), ULTA: 166.03 (-0.79), CMCSA: 62.41 (+0.05), GIS: 58.21 (-0.05), SNDK: 60.29 (-0.26)
Acorda 2Q Earnings & Revenues Top, Ampyra in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Jul 31, 2:43PM CDT
Acorda (ACOR) narrowed its 2015 guidance for Ampyra to $410 million - $420 million from $405 million - $420 million.
BIIB: 318.78 (+1.78), LGND: 108.26 (+0.48), AMAG: 63.90 (-0.87), ACOR: 34.36 (+0.13)
Price Isn't a Problem for Gilead Sciences
at The Street - Thu Jul 30, 10:00AM CDT
Drugmaker has one of the best showings of earnings season.
BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04), PFE: 36.06 (+0.33), MRK: 58.96 (+0.44), ABBV: 70.01 (-0.15), CELG: 131.25 (-0.63)
Attention New Biotech Investors: Biogen Inc's Recent Weakness Is Your Opportunity
Brian Feroldi, The Motley Fool - Motley Fool - Thu Jul 30, 8:38AM CDT
Investing in biotech stocks can be very intimidating for beginners, as many investors consider the word "biotech" to be synonymous with "risk". Press releases are filled with scientific jargon, many companies are losing money, and normal valuation...
BIIB: 318.78 (+1.78)
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Jul 30, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA
BIIB: 318.78 (+1.78), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), REGN: 553.66 (+6.56), XOMA: 0.73 (-0.08)
Troubled Stocks Go From Worst to First
at The Street - Wed Jul 29, 3:05PM CDT
Oil- and commodity-related shares perform well.
BIIB: 318.78 (+1.78), ESPR: 62.00 (-2.25), VDSI: 20.39 (-0.78), FB: 94.01 (-1.20), BEAT: 12.23 (+0.54), DATA: 104.74 (-2.10)
Sorry, No Fed Effect Today
at The Street - Wed Jul 29, 1:22PM CDT
The market did its usual jig on the news and went along its merry way.
BIIB: 318.78 (+1.78), ESPR: 62.00 (-2.25), VDSI: 20.39 (-0.78), FB: 94.01 (-1.20), BEAT: 12.23 (+0.54), DATA: 104.74 (-2.10)
Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 29, 10:48AM CDT
Last week saw several major biotech companies like Biogen (BIIB) and AbbVie (ABBV) reporting second quarter results.
BIIB: 318.78 (+1.78), VRTX: 135.00 (-0.46), ALXN: 197.44 (-1.85), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), REGN: 553.66 (+6.56), XOMA: 0.73 (-0.08)
Make Sure You Don't Get Caught in a Breakdown
at The Street - Wed Jul 29, 9:11AM CDT
Nothing much sticks out to the upside right now.
BIIB: 318.78 (+1.78), ESPR: 62.00 (-2.25), VDSI: 20.39 (-0.78), FB: 94.01 (-1.20), BEAT: 12.23 (+0.54), DATA: 104.74 (-2.10)
Stock Market News for July 29, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 9:10AM CDT
Benchmarks gained over 1% on Tuesday as investors focused on upbeat earnings results, ignoring the selloff in China’s stock market
BIIB: 318.78 (+1.78), F: 14.83 (-0.27), RIG: 13.26 (-0.69), GILD: 117.86 (-0.04), PFE: 36.06 (+0.33), COP: 50.34 (-1.73), XOM: 79.21 (-3.80), AMGN: 176.59 (+4.90), DD: 55.76 (+0.17), CVX: 88.48 (-4.55), SLB: 82.82 (-0.70), UPS: 102.36 (+0.96), CELG: 131.25 (-0.63)
5 Stocks Insiders Love Right Now
at The Street - Wed Jul 29, 7:14AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
RDUS: 78.32 (+3.08), ZINC: 8.28 (+0.21), BIIB: 318.78 (+1.78), MJN: 88.39 (-1.09), DPZ: 113.84 (unch)
Biogen Stock Remains Deeply Oversold
at The Street - Wed Jul 29, 5:00AM CDT
Three ways to profit after last Friday's crazy freefall.
BIIB: 318.78 (+1.78)
Gilead Q2 Earnings: KAPOW! BAM! BOOM! (Yes, That Good)
at The Street - Tue Jul 28, 3:15PM CDT
Gilead Sciences will not be blamed for a cooling of the biotech bull market, if any such thing exists.
BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04)
Amgen Stock Clears Buy Point Ahead Of Earnings
at Investor's Business Daily - Tue Jul 28, 1:33PM CDT
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first...
AGN: 331.15 (+2.28), BIIB: 318.78 (+1.78), SHPG: 266.81 (+4.29), MYL: 55.99 (-0.36), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), TEVA: 69.02 (-0.05)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Biogen, Inc.
PR Newswire - Tue Jul 28, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Biogen, Inc. ("Biogen" or the "Company"
(NasdaqGS: BIIB -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484. BIIB: 318.78 (+1.78)
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 165.83 (+6.66), BIIB: 318.78 (+1.78), LGND: 108.26 (+0.48), REGN: 553.66 (+6.56), EXEL: 5.73 (+0.19)
Watching Twitter for Moves at Teva and Biogen
at The Street - Tue Jul 28, 7:28AM CDT
Twitter sentiment predicts the big moves in two healthcare stocks-NYMX and BIIB.
BIIB: 318.78 (+1.78), TEVA: 69.02 (-0.05)
3 Big Biotech Buybacks That Investors Should Love
Brian Feroldi, The Motley Fool - Motley Fool - Tue Jul 28, 6:03AM CDT
Source: Images Of Money/Flickr Creative Commons. Large-cap biotech stocks have been on a tear over the past few years, crushing the overall market return. Thanks to strong execution and a slew of new drug launches, these companies have found...
BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04), CELG: 131.25 (-0.63)
Biogen & the Parkinson's Institute and Clinical Center reports strategic alliance to form novel tools and programmes to accelerate research and the development of new treatments in Parkinson's disease
M2 - Tue Jul 28, 5:33AM CDT
Biotechnology company Biogen (NasdaqGS:BIIB) revealed on Monday the establishment of a strategic alliance with the Parkinson's Institute and Clinical Center, to enhance the understanding of the underlying biology of Parkinson's disease (PD) and the creation of novel tools and programmes that could accelerate research and the development of new PD treatments.
BIIB: 318.78 (+1.78)
'Mad Money' Lightning Round: Sell, Sell, Sell SanDisk
at The Street - Tue Jul 28, 5:00AM CDT
Cramer thinks Cerus is a nice speculative stock, says to wait on ConocoPhillips and to buy 3M at $142.
CERS: 5.43 (+0.09), MMM: 151.34 (-0.23), BIIB: 318.78 (+1.78), ISIS: 54.93 (+1.76), MDSO: 53.80 (-0.22), COP: 50.34 (-1.73), SNDK: 60.29 (-0.26)
Jim Cramer's 'Mad Money' Recap: Beware the Market's FANGs
at The Street - Mon Jul 27, 7:16PM CDT
Cramer says this is the thinnest market we've seen in ages, and that's not good.
CERS: 5.43 (+0.09), MMM: 151.34 (-0.23), AMZN: 536.15 (-0.61), BIIB: 318.78 (+1.78), MDLZ: 45.13 (-0.14), EA: 71.55 (-0.75), SNA: 164.80 (+0.42), NKE: 115.22 (+0.21), MDSO: 53.80 (-0.22), FB: 94.01 (-1.20), FCX: 11.75 (-0.09), COP: 50.34 (-1.73), DIS: 120.00 (-0.03), NFLX: 114.31 (+2.75), ISIS: 54.93 (+1.76), QLIK: 40.46 (-0.04), KHC: 79.47 (+0.26), GOOGL: 657.50 (-7.06), ULTA: 166.03 (-0.79), CMCSA: 62.41 (+0.05), GIS: 58.21 (-0.05), SNDK: 60.29 (-0.26)
(0)
(0)